NEW YORK, April 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
World Biological Drugs Market 2012-2022
http://www.reportlinker.com/p0470101/World-Biological-Drugs-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Report Details
Your guide to biopharma industry trends and revenue prospects
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
Our new study investigates biotechnology in pharma - biological drugs (biopharmaceuticals, biologics). It lets you assess potential sales trends at world market, submarket, product and regional level to 2022.
How will 20 leading biologics - including Avastin, Enbrel, Humira and Herceptin - perform from 2012? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of submarkets to 2022, finding potential revenues:
• Monoclonal antibodies (MAbs) and fusion proteins
• Insulins
• Interferons
• Erythropoietins
• G-CSF agents
• Recombinant coagulation proteins
• Other therapeutic proteins
• Biosimilars.
Find coverage of biopharmaceutical R&D pipelines too, assessing trends and outlooks.
What does the future hold? Despite economic pressures, the biopharma industry has great potential from 2012. Our report shows you how the importance of biological drugs will increase from 2012 to 2022, with expanding revenues and shares of pharma sales.
There are many promising developments in biopharma, including antibody-drug conjugates and bispecific monoclonal antibodies. R&D pipelines for biologics are strong.
What about leading companies? Our work discusses Roche, Amgen, Novo Nordisk, Abbott and many other pharmaceutical companies, evaluating prospects of the industry and market.
How will biosimilars (follow-on protein products) affect the market? Many commercial opportunities remain, with high revenues from original branded drugs and biosimilars predicted to 2022. Our report shows and explains.
You can investigate the future of biopharmaceuticals now, discovering sales potential.
Our study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers in the work.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you get qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 212 tables and charts and three research interviews.
Eight ways World Biological Drugs Market 2012-2022 helps you
In particular, this study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 20 leading products
• See market forecasting to 2022 for US, Japan, EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, receiving detailed interviews.
There, you find an original mix of quantitative and qualitative analyses with independent predictions. Receive information that only our report contains.
Through our analytical methods we keep you informed about commercial trends and prospects, helping you to stay ahead.
Gain business research and analysis now for the biopharma market
Our study is for everybody needing industry and market analyses for biological drugs. You find data, trends and answers there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 World Biological Drugs Market Review
1.2 Summary of Report Contents
1.3 Research and Analysis Methods
2. Biological Drugs: Historical and Scientific Overview
2.1 Brief History of Biological Drugs
2.1.1 Monoclonal Antibodies
2.1.2 Therapeutic Proteins
2.2 Defining the Biotechnology Space
2.2.1 The Earliest Biological Drugs? The Case of Vaccines
2.2.2 What Constitutes a Biotechnological Drug?
2.3 Biological Drugs versus Small Molecules
3. World Biological Drugs Market: Overview 2012-2022
3.1 Whole Market Forecast 2012-2022
3.2 Market Segmentation, 2012-2022
4. Monoclonal Antibodies and Fusion Proteins Market 2012-2022
4.1 Monoclonal Antibodies and Fusion Proteins Market Forecast 2012-2022
4.2 Overview of Monoclonal Antibodies and Fusion Proteins Market, 2012
4.2.1 Antibodies and the Immune System
4.2.2 How Antibodies Work
4.2.3 Structure of Antibodies
4.2.4 The Fab Region
4.2.5 The Fc Region
4.2.6 Types of Therapeutic Antibody
4.2.7 Murine Monoclonal Antibodies
4.2.8 Chimeric and Humanised Monoclonal Antibodies
4.2.9 Fully-Human Monoclonal Antibodies
4.2.10 Fab Fragments
4.2.11 Fusion Proteins
4.2.12 Summary of Currently-Approved MAb and Fusion Protein Therapies, 2012
4.3 Leading MAb and Fusion Protein Products, 2012
4.3.1 Leading MAb and Fusion Protein Products: Market Forecast 2012-2022
4.3.2 Avastin (Roche), 2012-2022
4.3.3 Enbrel (Amgen), 2012-2022
4.3.4 Rituxan (Roche), 2012-2022
4.3.5 Humira (Abbott), 2012-2022
4.3.6 Herceptin (Roche), 2012-2022
4.3.7 Remicade (Johnson & Johnson), 2012-2022
4.3.8 Lucentis (Roche/Novartis), 2012-2022
4.3.9 Erbitux (Bristol-Myers Squibb/Merck KGaA), 2012-2022
4.3.10 Synagis (AstraZeneca), 2012-2022
4.3.11 Tysabri (Biogen Idec), 2012-2022
4.4 R&D Pipeline for MAbs and Fusion Proteins, 2012
4.4.1 Atacicept (Merck KGaA/ZymoGenetics)
4.4.2 Tabalumab (Eli Lilly)
4.4.3 Daclizumab (Biogen Idec)
4.4.4 Ocrelizumab (Biogen Idec)
4.4.5 Abagovomab (Menarini)
4.4.6 Ganitumab (Amgen)
4.4.7 Elotuzumab (Bristol-Myers Squibb)
4.4.8 Farletuzumab (Morphotek)
4.4.9 Inotuzumab Ozogamicin (Pfizer)
4.4.10 Necitumumab (Bristol-Myers Squibb)
4.4.11 Omnitarg (Roche)
4.4.12 Ramucirumab (Eli Lilly)
4.4.13 Rencarex (Prometheus Laboratories)
4.4.14 Trastuzumab-DM1 (Roche)
4.4.15 Teplizumab (MacroGenics)
4.4.16 ABthrax (raxibacumab) (Human Genome Sciences)
4.4.17 Bapineuzumab (Johnson & Johnson)
4.4.18 Solanezumab (Eli Lilly)
5. Therapeutic Proteins Market 2012-2022
5.1 Therapeutic Proteins Market Forecast 2012-2022
5.2 Major Sectors in the Therapeutic Proteins Market 2012-2022
5.2.1 Insulins: Market Forecast 2012-2022
5.2.2 Interferons: Market Forecast 2012-2022
5.2.3 Erythropoietins: Market Forecast 2012-2022
5.2.4 G-CSF: Market Forecast 2012-2022
5.2.5 Recombinant Coagulation Proteins: Market Forecast 2012-2022
5.2.6 Other Therapeutic Proteins: Market Forecast 2012-2022
5.3 Leading Therapeutic Protein Products, 2012
5.3.1 Leading Therapeutic Protein Products: Market Forecast 2012-2022
5.3.2 Neulasta/Neupogen (Amgen), 2012-2022
5.3.3 Epogen (Amgen), 2012-2022
5.3.4 Lantus (Sanofi), 2012-2022
5.3.5 Avonex (Biogen Idec), 2012-2022
5.3.6 Aranesp (Amgen), 2012-2022
5.3.7 Rebif (Amgen), 2012-2022
5.3.8 NovoRapid (Novo Nordisk), 2012-2022
5.3.9 Humalog (Novo Nordisk), 2012-2022
5.3.10 Pegasys (Novo Nordisk), 2012-2022
5.3.11 Advate (Baxter Healthcare), 2012-2022
5.4 R&D Pipeline for Therapeutic Proteins, 2012
5.4.1 Insulins Pipeline, 2012
5.4.2 Interferons Pipeline, 2012
5.4.3 Erythropoietins Pipeline, 2012
5.4.4 G-CSF Pipeline, 2012
5.4.5 Recombinant Coagulation Proteins Pipeline, 2012
5.4.6 Other Therapeutic Proteins Pipeline, 2012
6. Biosimilars Market 2012-2022
6.1 Market Overview 2012-2022
6.2 Overview of Biosimilars Field
6.3 Existing Biosimilars Products and Categories
6.3.1 Biosimilar Monoclonal Antibodies and Fusion Proteins
6.3.2 Biosimilar Insulins
6.3.3 Biosimilar Interferons
6.3.4 Biosimilar Erythropoietins
6.3.5 Biosimilar G-CSF
6.3.6 Biosimilar Recombinant Coagulation Proteins
6.3.7 Other Biosimilar Therapeutic Proteins
6.4 Development of the Regulatory Environment, 2012
6.4.1 European Regulation
6.4.2 US Regulation
6.4.3 Japanese Regulation
6.4.4 Chinese Regulation
6.4.5 Indian Regulation
7. Leading National Markets for Biological Drugs 2012-2022
7.1 The US Remains the Largest Market in 2012
7.2 The US Market 2012-2022
7.3 The EU5 Market 2012-2022
7.4 The Japanese Market 2012-2022
7.5 The Chinese Market 2012-2022
7.6 The Indian Market 2012-2022
8. Research Interviews
8.1 Interview with Dr Jason Kantor, Managing Director, RBC Capital Markets
8.1.1 On Progress in Antibody-Drug Conjugates
8.1.2 On Pharma Strategies for Next-Generation MAbs
8.1.3 On Competition between Different Types of Next-Generation MAbs
8.1.4 On Engineered Antibodies
8.1.5 On Prospects for Biosimilar Antibodies
8.1.6 On Next-Generation MAbs and Personalised Medicine
8.2 Interview with Dr Kathy Kowalchyk, Partner, Merchant & Gould P.C.
8.2.1 On Data Exclusivity for Biologics
8.2.2 On Development of the US Biosimilar Market
8.2.3 On Differences between the US and the EU
8.2.4 On Challenges with Biosimilar Development
8.3 Interview with Dr Robin Thorpe, Head, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC) [UK]
8.3.1 On Immunogenicity in Biosimilars
8.3.2 On Biosimilar Interferons
8.3.3 On Biosimilars in the UK
8.3.4 On Biosimilar Monoclonal Antibodies
9. World Biological Drugs Market: Qualitative Analysis and Conclusions of Our Study
9.1 Biotechnology has Greatly Benefited the Pharma Industry
9.2 Is The Medical Biotechnology Revolution Over?
9.3 Biosimilars: The Next Big Thing
9.4 Concerns About Costs of Biological Drugs
9.5 Concluding Thoughts
List of Tables
Table 2.1 Timeline of Key Discoveries in Biological Drugs
Table 2.2 Timeline of Key Discoveries in Monoclonal Antibodies
Table 2.3 Strengths and Weaknesses of Biological Drugs
Table 3.1 World Biological Drugs Market: Total Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.2 World Biological Drugs Market: Total Revenues ($bn), AGR (%), CAGR (%), 2016-2022
Table 3.3 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Table 3.4 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.5 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015
Table 3.6 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.7 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022
Table 4.1 MAbs and Fusion Proteins Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 4.2 MAbs and Fusion Proteins Market: Total Revenues ($bn), AGR (%), CAGR (%), 2016-2022
Table 4.3 Classes of MAb and Fusion Protein Product, 2012
Table 4.4 Murine Antibody Products on the Market, 2012
Table 4.5 Chimeric Antibody Products on the Market, 2012
Table 4.6 Humanised Antibody Products on the Market, 2012
Table 4.7 Fully-Human Antibody Products on the Market, 2012
Table 4.8 Fab Fragment Products on the Market, 2012
Table 4.9 Fusion Protein Products on the Market, 2012
Table 4.10 MAbs and Fusion Proteins Approved in the US, 1986-2011
Table 4.11 Some MAbs and Fusion Proteins Approved Outside the US, 2005-2009
Table 4.12 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), Market Shares (%), 2010
Table 4.13 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.14 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), Market Shares (%), 2015
Table 4.15 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.16 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), Market Shares (%), 2022
Table 4.17 Avastin: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.18 Avastin: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.19 Enbrel: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.20 Enbrel: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.21 Rituxan: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.22 Rituxan: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.23 Humira: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.24 Humira: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.25 Herceptin: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.26 Herceptin: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.27 Remicade: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.28 Remicade: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.29 Lucentis: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.30 Lucentis: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.31 Erbitux: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.32 Erbitux: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.33 Synagis: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.34 Synagis: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 4.35 Tysabri: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 4.36 Tysabri: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.1 Therapeutic Proteins Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 5.2 Therapeutic Proteins Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2022
Table 5.3 Leading Sectors in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2010
Table 5.4 Therapeutic Proteins Market, Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.5 Leading Sectors in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2015
Table 5.6 Therapeutic Proteins Market, Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 5.7 Leading Sectors in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2022
Table 5.8 Insulins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.9 Insulins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.10 Interferons Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.11 Interferons Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.12 Erythropoietins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.13 Erythropoietins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.14 G-CSF Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.15 G-CSF Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.16 Recombinant Coagulation Proteins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.17 Recombinant Coagulation Proteins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.18 Other Therapeutic Proteins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.19 Other Therapeutic Proteins Sector: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.20 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2010
Table 5.21 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.22 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2015
Table 5.23 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 5.24 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2022
Table 5.25 Neulasta/Neupogen: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.26 Neulasta/Neupogen: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.27 Epogen: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.28 Epogen: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.29 Lantus: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.30 Lantus: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.31 Avonex: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.32 Avonex: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.33 Aranesp: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.34 Aranesp: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.35 Rebif: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.36 Rebif: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.37 NovoRapid: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.38 NovoRapid: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.39 Humalog: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.40 Humalog: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.41 Pegasys: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.42 Pegasys: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.43 Advate: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.44 Advate: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 5.45 Late-Stage Therapeutic Proteins Pipeline, 2012
Table 6.1 Biosimilars Market: Total Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 6.2 Biosimilars Market: Total Revenues ($bn), AGR (%), CAGR (%), 2016-2022
Table 6.3 Biosimilars Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Table 6.4 Patent Expiry Dates for Leading Monoclonal Antibodies and Fusion Proteins
Table 6.5 Patent Expiry Dates for Leading Insulin Products
Table 6.6 Patent Expiry Dates for Leading Interferon Products
Table 6.7 Patent Expiry Dates for Leading Erythropoietin Products
Table 6.8 Patent Expiry Dates for Leading G-CSF Products
Table 7.1 Regional Breakdown of the Biological Drugs Market, Revenues ($bn), Market Shares (%) 2010
Table 7.2 Regional Breakdown of the Biological Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 7.3 Regional Breakdown of the Biological Drugs Market, Revenues ($bn), Market Shares (%), 2015
Table 7.4 Regional Breakdown of the Biological Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 7.5 Regional Breakdown of the Biological Drugs Market, Revenues ($bn), Market Shares (%), 2022
Table 7.6 US Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 7.7 US Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 7.8 EU5 Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 7.9 EU5 Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 7.10 Japanese Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 7.11 Japanese Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 7.12 Chinese Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 7.13 Chinese Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 7.14 Indian Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 7.15 Indian Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2022
Table 9.1 Strengths and Weaknesses of the Biological Drugs Market, 2012
Table 9.2 Opportunities and Threats in the Biological Drugs Market, 2012
List of Figures
Figure 3.1 World Biological Drugs Market: Total Revenues ($bn), 2010-2015
Figure 3.2 World Biological Drugs Market: Total Revenues ($bn), 2016-2022
Figure 3.3 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Figure 3.4 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), 2010-2015
Figure 3.5 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015
Figure 3.6 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), 2016-2022
Figure 3.7 World Biological Drugs Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022
Figure 4.1 MAbs and Fusion Proteins Market: Revenues ($bn), 2010-2015
Figure 4.2 MAbs and Fusion Proteins Market: Revenues ($bn), 2016-2022
Figure 4.3 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), Market Shares (%), 2010
Figure 4.4 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), 2010-2015
Figure 4.5 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), Market Shares (%), 2015
Figure 4.6 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), 2016-2022
Figure 4.7 Leading Products in the MAbs and Fusion Proteins Segment: Revenues ($bn), Market Shares (%), 2022
Figure 4.8 Avastin: Revenues ($bn), 2010-2015
Figure 4.9 Avastin: Revenues ($bn), 2016-2022
Figure 4.10 Enbrel: Revenues ($bn), 2010-2015
Figure 4.11 Enbrel: Revenues ($bn), 2016-2022
Figure 4.12 Rituxan: Revenues ($bn), 2010-2015
Figure 4.13 Rituxan: Revenues ($bn), 2016-2022
Figure 4.14 Humira: Revenues ($bn), 2010-2015
Figure 4.15 Humira: Revenues ($bn), 2016-2022
Figure 4.16 Herceptin: Revenues ($bn), 2010-2015
Figure 4.17 Herceptin: Revenues ($bn), 2016-2022
Figure 4.18 Remicade: Revenues ($bn), 2010-2015
Figure 4.19 Remicade: Revenues ($bn), 2016-2022
Figure 4.20 Lucentis: Revenues ($bn), 2010-2015
Figure 4.21 Lucentis: Revenues ($bn), 2016-2022
Figure 4.22 Erbitux: Revenues ($bn), 2010-2015
Figure 4.23 Erbitux: Revenues ($bn), 2016-2022
Figure 4.24 Synagis: Revenues ($bn), 2010-2015
Figure 4.25 Synagis: Revenues ($bn), 2016-2022
Figure 4.26 Tysabri: Revenues ($bn), 2010-2015
Figure 4.27 Tysabri: Revenues ($bn), 2016-2022
Figure 5.1 Therapeutic Proteins Market: Revenues ($bn), 2010-2015
Figure 5.2 Therapeutic Proteins Market: Revenues ($bn), 2016-2022
Figure 5.3 Leading Sectors in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2010
Figure 5.4 Therapeutic Proteins Market, Breakdown by Sector: Revenues ($bn), 2010-2015
Figure 5.5 Leading Sectors in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2015
Figure 5.6 Therapeutic Proteins Market, Breakdown by Sector: Revenues ($bn), 2016-2022
Figure 5.7 Leading Sectors in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2022
Figure 5.8 Insulins Sector: Revenues ($bn), 2010-2015
Figure 5.9 Insulins Sector: Revenues ($bn), 2016-2022
Figure 5.10 Interferons Sector: Revenues ($bn), 2010-2015
Figure 5.11 Interferons Sector: Revenues ($bn), 2016-2022
Figure 5.12 Erythropoietins Sector: Revenues ($bn), 2010-2015
Figure 5.13 Erythropoietins Sector: Revenues ($bn), 2016-2022
Figure 5.14 G-CSF Sector: Revenues ($bn), 2010-2015
Figure 5.15 G-CSF Sector: Revenues ($bn), 2016-2022
Figure 5.16 Recombinant Coagulation Proteins Sector: Revenues ($bn), 2010-2015
Figure 5.17 Recombinant Coagulation Proteins Sector: Revenues ($bn), 2016-2022
Figure 5.18 Other Therapeutic Proteins Sector: Revenues ($bn), 2010-2015
Figure 5.19 Other Therapeutic Proteins Sector: Revenues ($bn), 2016-2022
Figure 5.20 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2010
Figure 5.21 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), 2010-2015
Figure 5.22 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2015
Figure 5.23 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), 2016-2022
Figure 5.24 Leading Products in the Therapeutic Proteins Segment: Revenues ($bn), Market Shares (%), 2022
Figure 5.25 Neulasta/Neupogen: Revenues ($bn), 2010-2015
Figure 5.26 Neulasta/Neupogen: Revenues ($bn), 2016-2022
Figure 5.27 Epogen: Revenues ($bn), 2010-2015
Figure 5.28 Epogen: Revenues ($bn), 2016-2022
Figure 5.29 Lantus: Revenues ($bn), 2010-2015
Figure 5.30 Lantus: Revenues ($bn), 2016-2022
Figure 5.31 Avonex: Revenues ($bn), 2010-2015
Figure 5.32 Avonex: Revenues ($bn), 2016-2022
Figure 5.33 Aranesp: Revenues ($bn), 2010-2015
Figure 5.34 Aranesp: Revenues ($bn), 2016-2022
Figure 5.35 Rebif: Revenues ($bn), 2010-2015
Figure 5.36 Rebif: Revenues ($bn), 2016-2022
Figure 5.37 NovoRapid: Revenues ($bn), 2010-2015
Figure 5.38 NovoRapid: Revenues ($bn), 2016-2022
Figure 5.39 Humalog: Revenues ($bn), 2010-2015
Figure 5.40 Humalog: Revenues ($bn), 2016-2022
Figure 5.41 Pegasys: Revenues ($bn), 2010-2015
Figure 5.42 Pegasys: Revenues ($bn), 2016-2022
Figure 5.43 Advate: Revenues ($bn), 2010-2015
Figure 5.44 Advate: Revenues ($bn), 2016-2022
Figure 6.1 Biosimilars Market: Total Revenues ($bn), 2010-2015
Figure 6.2 Biosimilars Market: Total Revenues ($bn), 2016-2022
Figure 6.3 Biosimilars Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Figure 7.1 Regional Breakdown of the Biological Drugs Market, Revenues ($bn), Market Shares (%) 2010
Figure 7.2 Regional Breakdown of the Biological Drugs Market: Revenues ($bn), 2010-2015
Figure 7.3 Regional Breakdown of the Biological Drugs Market, Revenues ($bn), Market Shares (%), 2015
Figure 7.4 Regional Breakdown of the Biological Drugs Market: Revenues ($bn), 2016-2022
Figure 7.5 Regional Breakdown of the Biological Drugs Market, Revenues ($bn), Market Shares (%), 2022
Figure 7.6 US Market: Revenues ($bn), 2010-2015
Figure 7.7 US Market: Revenues ($bn), 2016-2022
Figure 7.8 EU5 Market: Revenues ($bn), 2010-2015
Figure 7.9 EU5 Market: Revenues ($bn), 2016-2022
Figure 7.10 Japanese Market: Revenues ($bn), 2010-2015
Figure 7.11 Japanese Market: Revenues ($bn), 2016-2022
Figure 7.12 Chinese Market: Revenues ($bn), 2010-2015
Figure 7.13 Chinese Market: Revenues ($bn), 2016-2022
Figure 7.14 Indian Market: Revenues ($bn), 2010-2015
Figure 7.15 Indian Market: Revenues ($bn), 2016-2022
Companies Listed
Abbott Laboratories
Adamis
Affymax
Agennix
Alexion
Alkermes
Alnylam
Amarillo Biosciences
Ambrx
American Society of Clinical Oncology
Amerisource Bergen
Amgen
Apotex
Arrow
Astellas
AstraZeneca
Baxter Healthcare
Bayer
Becton Dickinson
Beijing Shuanglu
BGI (China)
Bio Sidus
Biocon
Biogen Idec
BioGeneriX
Biolex Therapeutics
BioMarin
Biopartners
BioSante Pharmaceuticals
BioTech Pharma
Biotechnology Regulatory Authority of India (BRAI)
Bioton
Boehringer Ingelheim
Bristol-Myers Squibb
Cangene
Catalyst Biosciences
CCL Pharmaceuticals
Celgene
Cell Control
Cell Therapeutics
Cellegy
Celltech
Celtic Pharma
Centocor Ortho Biotech
Chengdu Hoist Hitech
Chiron
Chugai
CinnaGen
Cipla
CJ Corporation
Co-Genesys
CSL Behring
CT Arzneimittel
Dainippon Sumitomo
Dendreon
Dompé
Dong-A
Dr. Reddy's Laboratories
Dyax
Eisai
Élan
Eli Lilly
Elusys
Endo
Esteve
Eurofarma
European League Against Rheumatism
European Medicines Agency (EMEA/EMA)
Facet Biotech
Feron
Food and Drug Administration (US FDA)
Fresenius
Genentech
GeneScience
Genesis
Genetics Institute
Genex
GenMab
Genzyme
Getz Pharma
Gilead Sciences
GKV Spitzenverband (Germany)
GlaxoSmithKline
GlycoFi
GTC Biotherapeutics
Halozyme
HanAll Biopharma
Hanmi Pharmaceutical
Helix BioPharma
Hexal
Hoechst Marion Roussel
Hospira
Hualida Biotech
Human Genome Sciences
ImClone Systems
Immunex
ImmunoGen
Inhibitex
Inspiration Biopharmaceuticals
Intarcia Therapeutics
Intas Biopharmaceuticals
International Nephrology Network
Ipsen
Isis Pharmaceuticals
Isu Abxis
JCR Pharmaceuticals
Johnson & Johnson
King Pharmaceuticals
Kissei
Kuros
Kyowa Hakko Kirin
LG Life Sciences
Lipocine
Lipoxen
Lundbeck
Lupin Pharma
MacroGenics
Maxygen
Medice
MedImmune
Medixion
Medtronic
Megapharm
Menarini
Mentrik
Merchant & Gould P.C.
Merck & Co.
Merck BioVentures
Merck KGaA
Merck Serono
Ministry of Health, Labour and Welfare (MHLW, Japan)
Mitsubishi Tanabe
Morphotek
Myriad
National Institute for Biological Standards and Control (NIBSC, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Neose Technologies
Neurochem
NovaQuest
Novartis
Novo Nordisk
NPS Pharmaceuticals
NsGene
Octagon
Osiris Therapeutics
PDL Biopharma
Peptech
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmasset
Pharming
Prana Biotechnology
Prometheus Laboratories
ProStrakan
Proteon
Qilu
Quintiles Transnational
Ratiopharm
RBC Capital Markets
Regeneron Pharmaceuticals
Reliance Life Sciences
Roche
Sandoz
Sanofi
Schering-Plough
Seattle Genetics
Shire
Solvay
Spectrum
Stada
Stanford University
State Food and Drug Administration (China)
SurModics
Swedish Orphan Biovitrum (Sobi)
Syntonix
Takeda
Targacept
TauRx
Teva Pharmaceutical Industries
The National Hemophilia Foundation (US)
Tonghua Dongbao
TPG-Axon Capital
Transkaryotic Therapies
TransPharma Medical
TransTech
UCB
University Hospital of Tubingen
University of Leiden
University of Tokyo
Vertex Pharmaceuticals
ViroMed
Walter and Eliza Hall Institute
Warren Pharmaceuticals
Wilex
Wockhardt
Wyeth
Xencor
XOMA
Ypsomed
Zenyaku Kogyo
Zilip-Pharma
ZymoGenetics
To order this report:
Drug and Medication Industry: World Biological Drugs Market 2012-2022
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article